0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Apo-A1

Apo-A1

Brief Information

Name:Apolipoprotein A-I
Target Synonym:Apolipoprotein A-I(1-242),APOA1,ProapoA-I,Apo-AI,Apolipoprotein A1,Apo(A),ApoA-I,Apolipoprotein A-I,HPALP2,Epididymis Secretory Sperm Binding Protein
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
AP1-H5225 Human Human Apo-A1 Protein, His Tag
AP1-H5225-structure
AP1-H5225-sds

Synonym Name

Apolipoprotein A-I,APOA1,MGC117399

Background

ApoA1 is also known as apolipoprotein A-I, ApoA-I , and is the major protein component of high density lipoprotein (HDL) in plasma. It has a specific role in lipid metabolism. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterol acyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. In addition, it has been shown that ApoA1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Fx-5A Fx-5A Phase 1 Clinical Kinemed Cardiovascular Diseases Details
CER-001 CER-001 Phase 3 Clinical Cerenis Homozygous familial hypercholesterolemia; Atherosclerosis; Acute Coronary Syndrome; Heterozygous familial hypercholesterolemia; Hypoalphalipoproteinemias; Lipid Metabolism Disorders Details
SLN-360 Phase 1 Clinical Silence Therapeutics Plc Dyslipidemias; Hyperlipidemias Details
Pelacarsen TQJ-230; ISIS-681257; IONIS-681257 Phase 3 Clinical Ionis Pharmaceuticals Inc, Akcea, Isis Pharmaceuticals Kidney Diseases; Hyperlipoproteinaemia type IIa; Cardiovascular Diseases Details

This web search service is supported by Google Inc.

totop